This products is free for those who attended FNCE® 2019.
The prevalence and adverse effects of cancer cachexia are well-established in the nutrition community, with the presence of sarcopenia, or loss of skeletal muscle mass, as one of its defining characteristics. A co-diagnosis of sarcopenia with cancer is associated with poorer tolerance of treatment, poorer response to treatment, and negative outcomes as a whole. This session will present the science regarding the development of sarcopenia in the cancer patient, as well as strategies for RDNs to identify sarcopenia in oncology patients. Further, this session will identify practical applications of nutrition interventions to modulate sarcopenia, including the prevention of catabolism post-operatively in a variety of patient populations.
Planned with the Oncology Nutrition DPG
CPE Level: 3 - Advanced
Learning Need Codes: 5150, 3030, 2070
- 10.2.2 Works collaboratively with interdisciplinary team to identify and implement valid and reliable nutrition assessment tools to support access to care.
- 8.1.3 Integrates knowledge of macronutrients and micronutrients for absorption, digestion and metabolism throughout the life span in practice.
- 8.3.6 Keeps abreast of current nutrition and dietetics knowledge and trends.
- Define sarcopenia and discuss its impact on body composition, nutritional status, and overall outcomes of cancer patients.
- Identify specific nutrition interventions for sarcopenic cancer patients to improve nutritional status and treatment outcomes.
- Discuss the role of nutrition in minimizing catabolism post-operatively and in cancer patients.
- Caitlin Benda, MBA, MS, RD, CSO
- Jill Hamilton-Reeves, PhD, RD, CSO
- Vickie Baracos, PhD